Close Menu

NEW YORK – Gilead company Kite said on Thursday that it has submitted a supplemental biologics license application to the US Food and Drug Administration for its autologous CAR T-cell therapy brexucabtagene autoleucel (Tecartus) as a treatment for relapsed or refractory B-cell precursor acute lymphoblastic lymphoma (ALL).

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.